objective. To describe the frequency of selected antimicrobial resistance patterns among pathogens causing device-associated and procedure-associated healthcare-associated infections (HAIs) reported by hospitals in the National Healthcare Safety Network (NHSN).
it is managed by the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention. It integrates 3 former systems, the National Nosocomial Infections Surveillance (NNIS) system, the Dialysis Surveillance Network, and the National Surveillance System for Healthcare Workers, into a single system. In contrast to the NNIS system, the NHSN is designed to allow for surveillance of selected HAI data at locations other than intensive care units (ICUs), in hospitals and other types of healthcare facilities. Therefore, because of differences in the surveillance methodology of, and in the healthcare facilities reporting to, the NNIS system and the NHSN, the percentage of HAIs caused by antimicrobial-resistant pathogens reported to each system may not be comparable. A summary of device-associated infection rates reported to the NHSN has been published. 10 The purpose of this report is to describe the scope and magnitude of select antimicrobial-resistant pathogens among infections reported to the device-and procedure-associated modules of the NHSN.
methods
We analyzed data that hospitals reported from January 2006 through October 2007 to the device-and procedure-associated modules of the Patient Safety Component of the NHSN. 11 HAI data on postprocedure pneumonia were excluded from further analysis because they accounted for less than 1% of the infections reported during this time period.
NHSN Methodology
After completing NHSN training, healthcare facility personnel collect and report data on a monthly basis using standardized methods and definitions specific to the NHSN module(s) selected. 11 At least 6 months of data per year compliant with at least 1 module must be submitted to maintain active status in the NHSN.
For the device-associated module, patients in the selected patient care areas are monitored for 1-3 types of HAI: central line-associated bloodstream infection (CLABSI), catheter-associated urinary tract infection (CAUTI), or ventilator-associated pneumonia (VAP). Denominator data from the specific types of patient care areas are also collected. For the procedure-associated module, patients undergoing the selected surgical procedures are monitored for the development of either surgical site infection (SSI) or postprocedure pneumonia, or both. Procedure-specific denominator data are collected. HAIs are identified using standardized definitions that combine laboratory, clinical, and radiographic criteria, if applicable. 11
Pathogens and Susceptibility Data
Microbiology data provided by the healthcare facility's designated clinical microbiology laboratory are collected for each HAI identified. The methods used for organism identification and antimicrobial susceptibility testing may vary between lab-oratories in different facilities. Up to 3 organisms per HAI were reported. Laboratories were expected to use Clinical and Laboratory Standards Institute standards for antimicrobial susceptibility testing; 12 data for each pathogenic isolate were reported to the NHSN using the following category interpretations: intermediate, resistant, susceptible, or not tested. In some cases, resistance was defined using data from a single antimicrobial test result (resistance to ceftazidime, amikacin, or cefepime in P. aeruginosa pathogenic isolates; resistance to oxacillin in S. aureus pathogenic isolates; and resistance to either vancomycin or ampicillin in Enterococcus pathogenic isolates). In other cases, because laboratories test different antimicrobial agents within a class of antibiotics, resistance was defined using data from at least one of several agents within the same antibiotic class. Specifically, we defined resistance as follows: for fluoroquinolone resistance among P. aeruginosa and E. coli pathogenic isolates, the organisms were resistant to either ciprofloxacin, levofloxacin, ofloxacin, or moxifloxacin; for piperacillin resistance among P. aeruginosa pathogenic isolates, the organisms were resistant to either piperacillin or piperacillin-tazobactam; for carbapenem resistance among P. aeruginosa and Acinetobacter baumannii pathogenic isolates, the organisms were resistant to imipenem or meropenem; for carbapenem resistance among E. coli, Klebsiella pneumoniae, and Klebsiella oxytoca pathogenic isolates, the organisms were resistant to imipenem, meropenem, or ertapenem; and for extended-spectrum cephalosporin resistance among E. coli, K. pneumoniae, K. oxytoca, and A. baumannii pathogenic isolates, the organisms were resistant to either ceftriaxone or ceftazidime. A subset of the organisms listed above were classified as multidrug resistant, including MRSA, vancomycin-resistant Enterococcus, extended-spectrum cephalosporin-resistant K. pneumoniae and E. coli, and carbapenem-resistant P. aeruginosa, A. baumannii, K. pneumoniae, K. oxytoca, and E. coli. This classification was based on the recognition that the mechanisms of resistance in these phenotypes confer resistance to multiple classes of antimicrobial agents. 12 This list is not all-inclusive but includes pathogens of epidemiologic concern.
Selection of Pathogen-Antimicrobial Combinations of Concern
Pathogen-antimicrobial combinations selected for evaluation in this report were chosen on the basis of their greater frequency, their higher degree of clinical importance, and consideration of emerging antimicrobial resistance. To describe the variability in the incidence rates of antimicrobial resistance among specific reporting patient care areas, 4 pathogenantimicrobial combinations were selected for each type of device-associated HAI.
Statistical Analysis
Data were analyzed using SAS software, version 9.1 (SAS). For device-associated infections, the total number of HAIs and their distribution by type of hospital, patient care area, and procedure were calculated. For procedure-associated infection, the total number of pathogens and their distribution by type of HAI and surgical procedure were calculated. For each type of HAI, the percentage of pathogenic isolates re-sistant to antimicrobial agents (hereafter, the resistance percentage) was calculated for the pathogen-antimicrobial combinations by pooling data from all NHSN hospitals for this time period (ie, the sum of pathogenic isolates that were found to be resistant divided by the sum of pathogenic isolates that were tested, multiplied by 100). If fewer than 30 isolates were tested for antimicrobial susceptibility overall, the data were considered of low accuracy and therefore not reported, consistent with Clinical and Laboratory Standards Institute recommendations. 13 The resistance percentage is reported by type of HAI. Additionally, if the resistance percentage did not differ between the types of device-associated infections for a specific pathogen-antimicrobial combination, a pooled device-associated resistance percentage was also reported. Differences in the resistance percentages were compared across types of HAI using the x 2 test for independence (ie, comparing the lowest and highest resistance percentages for device-associated HAIs, and comparing the pooled device-associated HAI resistance percentages and SSI resistance percentages).
Location-specific incidence rates of HAI due to selected antimicrobial-resistant pathogens were also calculated for MRSA (CLABSI and VAP), vancomycin-resistant Enterococcus faecium (CLABSI and CAUTI), extended-spectrum cephalosporin-resistant K. pneumoniae (CLABSI, CAUTI, and VAP), carbapenem-resistant A. baumannii (CLABSI, CAUTI, and VAP), and carbapenem-resistant P. aeruginosa (CAUTI and VAP). For these rates, only locations reporting more than 50 device-days were included in the calculations. Pooled mean incidence rates for specific patient care areas included data from all healthcare facilities reporting from those patient care areas. The range of incidence rates for a specific patient care area was reported only if more than 20 healthcare facilities reported data for that patient care area.
To estimate the effects of unique recognized antimicrobial resistance patterns reported from certain geographic areas, and state mandatory reporting requirements on data in the current pool, we attempted to determine the relative contribution of facilities from New York on the magnitude of resistance. This was done by comparing the pooled deviceassociated HAI resistance percentage while including and excluding data from New York facilities. We focused on data from this state because all New York hospitals were mandated to use the NHSN for reporting HAI data beginning January 2007 and because recent reports have described carbapenemase-producing Klebsiella species as a problem among some New York hospitals. 14 
results

Distribution of Infections
From January 2006 through October 2007, a total of 28,502 HAIs were reported to the NHSN: 10,064 (35.3%) were cases of CLABSI, 8,579 (30.1%) were cases of CAUTI, 4,524 (15.9%) were cases of VAP, 5,291 (18.6%) were cases of SSI, and 44 (0.2%) were cases of postprocedure pneumonia (data not shown). The 463 hospitals that reported 1 or more HAIs to the NHSN during this time period were predominantly large ( Table 1) : 412 (89%) were general acute care hospitals, 309 (67%) had between 200 and 1,000 beds, and 151 (33%) had less than 200 beds. Hospitals from 42 states were involved in the reporting to the NHSN. Most of the HAIs reported (19, 390 [68%] of 28,502) were from hospitals in the northeastern and southern United States, which comprised 73% of the total number of hospitals.
Most patients with HAI were adults; 21,576 (85%) of the 25,384 patients were older than 20 years of age. Patients 0-3 years of age were mainly diagnosed with CLABSI (which represented 78% of HAIs for that age group). The HAIs were reported from 1,428 unique locations representing 10 general types of patient care areas within the 463 NHSN hospitals. Most device-associated HAIs were reported from ICUs: medical-surgical ICUs (23%), medical ICUs (13%), surgical ICUs (12%), neonatal ICUs (11%), trauma ICUs (7%), cardiothoracic surgical ICUs (6%), medical cardiac ICUs (5%), pediatric ICUs (4%), neurosurgical ICUs (4%), and burn ICUs (3%). The remaining 12% of device-associated HAIs were reported from specialty care areas (3%) and other inpatient non-ICU areas (ie, medical-surgical wards [5%] and other inpatient wards [4%]) ( Table 2 ). The majority of procedure-associated HAIs were identified on inpatient surgical wards (data not shown), and most were associated with 1 of 4 major procedure types: cardiac surgery (29%), abdominal surgery (26%), orthopedic surgery (18%), and neurosurgery (12%) ( Table 3) .
Pathogen Distribution
From 28,502 cases of HAI, a total of 33,848 pathogenic isolates were recovered and reported: 29,448 (87%) were bacteria, and 4,400 (13%) were fungi (Table 4 ). Overall, 16.4% of infections were polymicrobial and varied slightly by type of HAI: 20% of cases of SSI were polymicrobial, 21% of cases of VAP, 11% of cases of CLABSI, and 8% of cases of CAUTI.
Overall, the majority of isolates (70%) were either coagulase-negative staphylococci (15%), S. aureus (15%), Enterococcus species (12%), Candida species (11%), E. coli (10%), or P. aeruginosa (8%) ( Table 4 ). The rank-order distribution of the selected pathogens varied by type of HAI but did not vary significantly when stratified by patient care area or by criteria used to identify each HAI (except for cases of CLABSI, for which criterion 2 is specific for common skin contaminant; data not shown). 11 For cases of SSI, the distribution of pathogens varied only slightly when stratified by type of SSI (superficial incisional, deep incisional, or organ space; data not shown) but varied signficantly when stratified by type of surgery (Table 5 ). Coagulase-negative staphylococci and S. aureus were the most prevalent pathogens causing SSI for most types of surgery, but gram-negative rods and enterococci were the more prevalent pathogens causing SSI following abdominal surgery. Enterococci were associated with approximately one-third of cases of SSI following transplant surgery.
Antimicrobial Resistance Percentages
Antimicrobial susceptibility testing data were received for most of the pathogenic isolates reported; the proportion of pathogenic isolates with test results varied by antimicrobial agent, pathogen, and type of HAI. 6 and 7) . Pooled mean resistance percentages for the pathogen-antimicrobial combinations are shown in Tables 6 and 7 . For 13 of 22 antimicrobial-resistant phenotypes evaluated, the resistance percentage was comparable between all types of device-associated HAIs, and an overall pooled device-as-sociated resistance percentage is presented (Table 6 ). However, there were some exceptions. Compared with cases of CAUTI, cases of CLABSI had a higher percentage of Enterococcus pathogenic isolates not otherwise specified that were resistant to vancomycin (18% vs 37%) and ampicillin (21.3% vs 40.7%), P. aeruginosa pathogenic isolates resistant to ceftazidime (12.6% vs 18.7%), and K. pneumoniae pathogenic isolates resistant to ceftriaxone or ceftazidime (21.2% vs 27.1%). Compared with cases of VAP, cases of CLABSI had a higher percentage of E. coli pathogenic isolates resistant to fluoroquinolones (22.7% vs 30.8%). Compared with cases of CLABSI and CAUTI, cases of VAP had a lower percentage of K. pneumoniae pathogenic isolates resistant to carbapenems (10.8% and 10.1% vs 3.6%). Compared with cases of CAUTI, cases of VAP had a higher percentage of A. baumannii pathogenic isolates resistant to carbapenems (25.6% vs 36.8%) and a higher percentage of E. coli pathogenic isolates resistant to ceftriaxone or ceftazidime (5.5% vs 11.0%). Compared with cases of CLABSI, cases of CAUTI had a higher percentage of E. coli pathogenic isolates resistant to carbapenems (0.9% vs 4.0%) ( Table 6 ). The resistance percentages were lower for pathogenic isolates recovered from patients with SSI than for pathogenic isolates recovered from patients with device-associated HAI, and these data are presented separately (Table  7) .
When evaluating the relative contribution of the New York hospitals to the pooled data, we found that the pooled re- sistance percentage for pathogen-antimicrobial combinations for all device-associated HAIs combined remained unchanged when healthcare facilities reporting from New York were excluded, with the exception of carbapenem-resistant K. pneumoniae pathogenic isolates, which changed from 8.7% to 5 % ( ). Because the exclusion of the New York hospitals P ! .001 did not affect the overall results reported, all of the tables include the data from New York.
Variability in the Incidence of HAIs With Select Antimicrobial-Resistant Pathogens
The pooled mean rates of infection with antimicrobial-resistant pathogens varied by type of patient care area for cases of CLABSI, CAUTI, and VAP, and these rates are reported separately (Tables 8-10 ). Data presented are limited to the more common antimicrobial-resistant pathogens, including some of the multidrug-resistant phenotypes; overall, the infection rate was very low. Also, in most cases, the majority of hospitals reported no antimicrobial-resistant HAIs (ie, the median rate was zero). For example, the median rate of MRSA CLABSI and of MRSA VAP was zero in all types of patient care areas, with the exception of MRSA VAP in trauma ICU and medical ICU (Tables 8 and 10 ). However, differences in the pooled mean rates were clearly evident by type of patient care area. For example, the rate of MRSA CLABSI (calculated as cases per 1,000 device-days) was low for inpatient medicalsurgical wards and was average for other ICUs (cardiac, medical, surgical, and trauma ICUs) and inpatient medical wards. The highest MRSA CLABSI rate was reported by burn ICUs (0.93 cases per 1,000 device-days).
For antimicrobial-resistant gram-negative rods causing CLABSI, CAUTI, and VAP, in almost all types of patient care areas, approximately 80% of units or more reported no cases of carbapenem-resistant A. baumannii or extended-spectrum cephalosporin-resistant K. pneumoniae (Tables 8-10 ). In all types of patient care areas, 70% of units or more reported no cases of carbapenem-resistant P. aeruginosa CAUTI or VAP (Tables 9 and 10 ). discussion This is the first antimicrobial resistance report from the NHSN. We found the pathogen distribution still closely parallels that of the NNIS reports from 1986 to 1999. 15, 16 The resistance percentages differ only slightly from the percentages found in historical data on ICU infections reported to the NNIS from 1986 to 2003. [15] [16] [17] [18] Compared with the historical NNIS reports, this NHSN report found a slightly lower re- 17 and for extended-spectrum cephalosporin-resistant P. aeruginosa (32% vs 13%-19% of pathogenic isolates), but a slightly higher resistance percentage for vancomycin-resistant Enterococcus (29% vs 33% of pathogenic isolates), extended-spectrum cephalosporin-resistant E. coli (6% vs 6%-11% of pathogenic isolates), extended-spectrum cephalosporin-resistant K. pneumoniae (21% vs 21%-27% of pathogenic isolates), and carbapenem-resistant P. aeruginosa (21% vs 25% of pathogenic isolates). 18 These current patterns seem to be similar to those found in national and international surveillance studies. [19] [20] [21] [22] [23] For device-associated infections and SSIs, the most prevalent organisms overall were gram-positive cocci (S. aureus, enterococci, and coagulase-negative staphylococci, which were associated with 40% of infections) and Candida species. For cases of CLABSI, CAUTI, and VAP, the ranking of the 4 most common pathogens is almost identical to that of the NNIS report published in 1999. 15 One notable exception is for VAP; A. baumannii now equals Enterobacter species, as the third most common pathogen. In contrast, the ranking of pathogens for ICU-associated HAIs from European studies reveals a greater contribution from E. coli and Pseudomonas species and a less prominent contribution from Enterococcus species 22, 23 and, in some cases, Candida species. 22 These differences may be explained by the use of different surveillance methods (the NHSN limits reports to device-and procedureassociated infections based on specific criteria, whereas other institutions may use any positive clinical culture result, which may represent either colonization or infection) or perhaps by geographic differences.
Overall, compared with studies from other surveillance systems involving ICUs from European and North American countries (including the United States), our pooled mean resistance percentages are similar for MRSA and, in some instances, for P. aeruginosa, but are higher for most other pathogens. 9, [19] [20] [21] [22] [23] [24] [25] For MRSA pathogenic isolates, resistance percentages as low as 20% have been reported from Canada 21 and as high as 80% from southern European countries, 23 but resistance percentages from ICUs in Europe and North America are comparable to ours (50%-60% of pathogenic isolates). 19, 20, 23 For Enterococcus species, the percentages of resistance to vancomycin that we found are higher overall than those from Europe and North America (33% vs 13%-28% of pathogenic isolates), 19, 20, 24, 25 as are the percentages we found for vancomycin-resistant E. faecium pathogenic isolates (80% vs 0.8% reported from France and 24% from Italy). 21 For the P. aeruginosa pathogenic isolates tested, the pooled mean resistance percentages for most antimicrobials were comparable with those of other studies in general, 9, [19] [20] [21] [23] [24] [25] [26] except for Italy, where a higher percentage of resistance to ceftazidime, cefepime, piperacillin, and fluoroquinolone has been reported. 21 However, the carbapenem resistance percentage was higher overall in this NHSN report. 9, 19, 20, 22, 23 Among Enterobacteriaceae pathogenic isolates, resistance to fluoroquinolones, extended-spectrum cephalosporins, and carbapenems was generally higher in our report, compared with other isolate-based testing systems both inside and outside the United States. 9, [19] [20] [21] [22] 24, 25 Among these reports, the notable exceptions included the higher percentage of extendedspectrum cephalosporin resistance among K. pneumoniae (29% of pathogenic isolates) and K. oxytoca (15% of pathogenic isolates) from Italy. 21 Also of note, no carbapenemresistant K. oxytoca pathogenic isolates were reported from any of these studies, and, similarly, only one study 9 reported any carbapenem-resistant K. pneumoniae pathogenic isolates. Our observed resistance percentages for carbapenem-resistant A. baumannii were also considerably higher than those from these other studies (33% vs 2%-21% of pathogenic isolates). 9, 19, 21 The NHSN received reports of this antimicrobial-resistant pathogen from 5%-25% of locations reporting cases of VAP, with higher percentages of reporting among burn and trauma ICUs ( Table 10 ). The high percentage of resistance to carbapenems observed among K. pneumoniae pathogenic isolates was of special concern. Previous laboratory-based surveillance studies evaluating bloodstream infections in hospitalized patients did not identify any pathogenic isolates of carbapenem-resistant Klebsiella species among a range of 161-765 pathogenic isolates. 19, 26, 27 We observed a range of resistance percentages (ie, 4%-11% of pathogenic isolates) among the different types of HAI, with the highest resistance percentages observed for pathogenic isolates associated with CLABSI. The first reports of carbapenem resistance among Klebsiella species started to appear from New York hospitals around 2004. 14 The resistance percentage for pathogenic isolates reported from New York hospitals was 21% and contributed to the percentages observed; however, when excluding the hospitals reporting from New York, the resistance percentage remained high (5% of pathogenic isolates), which suggests that this phenotype may be more widespread and more common than previously recognized (ie, the resistance percentage observed is not due solely to healthcare facilities reporting from a single geographic area).
Identification of some of these emerging resistance patterns should alert the infection control community to potential challenges they may face in coming years. However, although each of these described antimicrobial-resistant phenotypes is of concern, the frequency with which each causes HAIs is relatively low, compared with all other pathogens. Among all cases of HAI reported, the following multidrug-resistant pathogens accounted for approximately 16% of infections: MRSA, 8%; vancomycin-resistant E. faecium, 4%; carbapenem-resistant P. aeruginosa, 2%; extended-spectrum cephalosporin-resistant K. pneumoniae, 1%; extended-spectrum cephalosporin-resistant E. coli, less than 1%; and carbapenem-resistant A. baumannii, K. pneumoniae, K. oxytoca, and E. coli, each less than 1%.
A novel metric included in this report is a device-associated infection incidence density rate for selected antimicrobialresistant pathogens. Data were stratified by type of patient care area, because differences according to hospital location were evident. Further stratification (eg, by the number of beds in the hospital) may be possible as more data become available. The incidence density rate allows for assessment of the variability of antimicrobial resistance among device-associated infections in different patient care areas, and may provide an additional way to assess the efficacy of infection control practices in the future. In general, antimicrobial-re-sistant device-associated infections due to gram-positive pathogens was more widespread than infections due to gramnegative pathogens. However, overall, less than 50% of units reporting to each of the types of patient care areas reported any device-associated infection due to antimicrobial-resistant pathogens, suggesting that these types of infections are not represented equally among all reporting hospitals. As the NHSN hospitals continue to report cases of HAI during the next several years, the tracking of this distribution of resistant pathogens is needed to assess the utility of this metric.
Direct comparisons of this resistance-percentage data with the data reported in other studies and even with prior NNIS reports may not be informative for several reasons. First, the NHSN includes expansion to non-ICU patient care areas and no minimum bed size criterion for inclusion of a hospital as a member, in contrast to the NNIS system. Second, this NHSN analysis limits reports to device-and procedure-associated HAIs. Third, although the hospitals contributing data to the current report are similar to those that reported to the NNIS system (general, large, acute care hospitals), 28 they include more varied types of hospitals and patient care areas. This report and previous NNIS reports have a limitation in common: the patient population may not be representative of the US patient population as a whole, even though hospitals from 42 states are represented.
Additional limitations of this report include the fact that antimicrobial susceptibility testing was performed by laboratories servicing the hospitals, not by a central laboratory of the Centers for Disease Control and Prevention. Also, a few errors were identified in the data. We looked at the frequency of highly unlikely phenotypes and found a number of reports that noted carbapenem resistance in conjunction with extended-spectrum cephalosporin susceptibility among pathogenic isolates of K. pneumoniae and E. coli. These unlikely phenotypes were reported in only 0.46% of all K. pneumoniae pathogenic isolates, equivalent to 7.5% of the carbapenem-resistant K. pneumoniae pathogenic isolates reported, but were reported in 1.13% of all E. coli pathogenic isolates, equivalent to 66.7% of the carbapenem-resistant E. coli pathogenic isolates reported. These errors may be have been due to incorrect data entry and/or laboratory testing. In response to these findings, and to improve the reliability of the data entered into this system, an edit check will be incorporated, to warn if data on carbapenem resistance in conjunction with extended-spectrum cephalosporin susceptibility are entered. Lastly, accounting for the impact of mandated reporting on this antimicrobial resistance report will be an ongoing challenge. By January 2007, there were 2 states that had required all hospitals to report data to the NHSN, and this number continues to increase. In summary, this first report describes the scope, magnitude, and variability of certain antimicrobial-resistant pathogens associated with deviceor procedure-associated HAIs reported to the Patient Safety Component of the NHSN.
